• $.$$


Amended: Naturally Splendid Closes Private Placement Secures Laboratory Facility

September 21, 2020-06:30 AM EDT

VANCOUVER, British Columbia, September 21, 2020 -- Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 17,554,168 units (the “Units”) at $0.06 per Unit, for total gross proceeds of $1,053,250 (the “Offering”). Due to oversubscribed demand, the private placement financing was increased from 14,166,667 Units to 17,554,168.

READ FULL NEWS

Naturally Splendid Announces Biologic Definitive Agreement and Private Placement

September 2, 2020-09:05 AM EDT

Vancouver, British Columbia - The Newswire - September 2, 2020 - Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP)(OTC:NSPDF) is pleased to announce that it has entered into a Definitive Agreement with Vancouver-based Biologic Pharmamedical Research ("Biologic") to form a joint venture for the purpose offurther developing and pursuing phase 2 clinical studies for a potential COVID-19 treatment, utilizing one of Biologic's patented technologies as a candidate.

READ FULL NEWS

Amended: Naturally Splendid Reports Second Quarter Results for 2020

August 29, 2020-12:35 PM EDT

Vancouver, British Columbia - TheNewswire - August 28, 2020 - Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSX-V:NSP)(OTC:NSPDF) announces its unaudited financial results for the six months ended June 30, 2020. All amounts are in Canadian dollars and are prepared in accordance with International FinancialReporting Standards. Naturally Splendid recorded sales of $1,025,636 during the six months ended June 30, 2020, compared to $1,723,541 for the six months ended June 30, 2019. The Company's sales decreased byapproximately $698,000 over the same period last year.

READ FULL NEWS

Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial

August 10, 2020-08:53 AM EDT

VANCOUVER, British Columbia - TheNewswire - August 10, 2020 -- Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE") (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) advises that subsequent to Heath Canada issuing a No Objection Letter, they have requested specific protocol details regarding the Clinical Trial Application for CavaltinibTM, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the trial may commence.

READ FULL NEWS
?
This website collects data via Google Analytics. Click here to opt in. Click here to opt out.
×